Original communication| Volume 142, ISSUE 5, P741-748, November 2007

An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer


      Tissue samples from patients with pathologic (p) stage III colorectal cancer were tested for sensitivity to 5-fluorouracil (5-FU). On the basis of the results, patients were divided into 5-FU–sensitive and 5-FU–resistant groups, and both groups were treated with fluoropyrimidine (UFT) as postoperative adjuvant chemotherapy. Recurrence, 5-year survival rates, and 5-year recurrence-free survival rates were compared.


      The anticancer sensitivity test described in this study was carried out using tumor samples obtained surgically from 34 patients with curatively resectable colorectal cancer that had been diagnosed definitively as pstage III (IIIa, 23 patients; IIIb, 11 patients). Regardless of tumor sensitivity or resistance to 5-FU, all 34 patients were subsequently treated daily with UFT at 300 mg/day as postoperative adjuvant chemotherapy. Treatment was initiated 3 weeks after surgery and continued for 2 years.


      Of the 34 patients with pstage III colorectal cancer, the tumors of 16 (47%) were 5-FU–sensitive (S group) and 18 (53%) were 5-FU–resistant (R group). The recurrence rates in the S and R groups following postadjuvant therapy with UFT were 25% and 61%, respectively, which is a significantly lower response in the S group (P = .045). The odds ratio of recurrence in the R group vs. the S group was 4.71. The 5-year survival rate was 85.7% in the S group and 46.7% in the R group, but the difference was not significant (P = .066). The 5-year recurrence-free survival rate was significantly higher in the S group than in the R groups (71% vs. 32%, P = .010). According to Cox’s multivariate analysis of recurrence-free survival, the sensitivity test was significantly predictive.


      Administration of UFT as postoperative adjuvant therapy to 5-FU–resistant patients had no significant effect on outcome.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Francini G.
        • Petrioli R.
        • Lorenzini L.
        • Mancini S.
        • Armenio S.
        • Tanzini G.
        • et al.
        Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.
        Gastroenterology. 1994; 106: 899-906
        • IMPACT
        Efficacy of adjuvant fluorouracil and folinic acid in colon cancer.
        Lancet. 1995; 345: 939-944
        • O’Connel M.J.
        • Laurie J.A.
        • Kahn M.
        • Fitzgibbons Jr, R.J.
        • Erlichman C.
        • Shepherd L.
        • et al.
        Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
        J Clin Oncol. 1998; 16: 295-300
        • Kodaira S.
        • Kikuchi K.
        • Yasutomi M.
        • Takahashi T.
        • Hojo K.
        • Kato T.
        Postoperative adjuvant chemotherapy with mitomycin C and UFT for curative resected rectal cancer.
        Int J Clin Oncol. 1998; 3: 357-364
        • Kato T.
        • Ohashi Y.
        • Nakazato H.
        • Koike A.
        • Saji S.
        • Suzuki H.
        Efficacy of oral UFT as adjuvant chemotherapy curative resection of colorectal cancer: Multicentre prospective randomized trial.
        Langenbeck’s Arch Surg. 2002; 386: 575-581
        • Pazdur R.
        • Lassere Y.
        • Rhodes V.
        • Ajani J.A.
        • Sugarman S.M.
        • Patt Y.Z.
        • et al.
        Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma.
        J Clin Oncol. 1994; 12: 2296-2300
        • Saltz L.B.
        • Leichman C.G.
        • Young C.W.
        • Muggia F.M.
        • Conti J.A.
        • Spiess T.
        • et al.
        A fixed-ratio combination of uracil and tegafur (UFT) with low dose leucovorin.
        Cancer. 1995; 75: 782-785
        • Kondo T.
        • Imamura T.
        • Ichihashi H.
        In vitro test for sensitivity of tumor to carcinostatic agents.
        Gann. 1966; 57: 113-121
        • Salmon S.E.
        Human tumor colony assay and chemosensitivity testing.
        Cancer Treat Rep. 1984; 68: 117-125
        • Vescio R.A.
        • Redfern C.H.
        • Nelson T.J.
        • Ugortz S.
        • Stern P.H.
        • Hoffman R.M.
        In vitro-like drug responses of human tumors growing in three-dimensional gel-supported primary culture.
        Pro Natl Acad Sci USA. 1987; 84: 5029-5033
        • Suto A.
        • Kubota T.
        • Shimoyama Y.
        • Isibiki K.
        • Abe O.
        MTT assay with reference to the clinical effect of chemotherapy.
        J Surg Oncol. 1989; 42: 28-32
        • Schrag D.
        • Garewal H.S.
        • Burstein H.J.
        • Samson D.J.
        • VonHoff D.D.
        • Somerfield M.R.
        American society of clinical oncology technology assessment: Chemosensitivity and resistance assays.
        J Clin Oncol. 2004; 22: 3631-3638
        • Matsuoka H.
        A new method of three-dimensional chemosesivitivity test using thermoreversible gelation polymer (TGP) as culture material (in Japanese).
        St Marianna Med J. 1999; 27: 411-418
        • Yoshikawa T.
        • Tsukikawa S.
        Chemosenstivity test of human cancer cell lines in three-dimensional culture using thermoreversible gelation polymer(in Japanese).
        St Marianna Med J. 2000; 28: 477-486
        • Matsuoka H.
        • Nagaya M.
        • Tsukikawa S.
        • Yanagi Y.
        • Isogai A.
        • Kubota S.
        Repeated hepatic intra-arterial chemotherapy based on results of anticancer drug sensitivity test in patients with synchronous hepatic metastases from colorectal cancer.
        Surgery. 2006; 140: 387-395
        • Japanese Research Society for Cancer of Colon and Rectum
        General rules for clinical and pathological studies on cancer of the colon, rectum and anus.
        6th ed. Kanehara & Co, Japan1998
        • Mosmann T.
        Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
        J Immunol Methods. 1983; 65: 55-63
        • Carmichael J.
        • DeGraff W.G.
        • Gazdar A.F.
        Evaluation a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.
        Cancer Res. 1987; 47: 936-942
        • Ishiyama M.
        • Tominaga H.
        • Shiga M.
        • Sasamoto K.
        • Ohkura Y.
        • Ueno K.
        A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet.
        Biol Pharm Bull. 1996; 19: 1518-1520
        • Takamatsu N.
        The new colorimetric assay (WST-8) for cellular growth with aging and Alzheimer’s disease.
        Nippon Ronen Igakkai Zasshi. 1998; 35: 535-542
        • Japan Society for Cancer Therapy
        Criteria for the evaluation of the clinical effects of solid cancer chemotherapy.
        J Jpn Soc Cancer Ther. 1993; 28: 101-130
        • Japanese Society for Cancer of Colon and Rectum
        Guide-line for treatment of colorectal cancer.
        Kanehara & Co, Japan2005
        • Sadahiro S.
        • Mitomi T.
        • Noto T.
        • Kumada K.
        • Hiki Y.
        • Yamakawa T.
        Multicenter comparative study of the recurrence inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection(in Japanese).
        Jpn J Cancer Chemother. 2005; 32: 997-1005
        • Ohwada S.
        • Ikeya T.
        • Yokomori T.
        • Kusaba T.
        • Roppongi T.
        • Takahashi T.
        • et al.
        Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: A randomized controlled study.
        Br J Cancer. 2004; 90: 1003-1010
      1. Advanced Colorectal Cancer Meta-Analysis Project.
        J Clin Oncol. 1992; 10: 896-903
        • Seifert P.
        • Baker L.H.
        • Reed M.L.
        • Vaitkevicius V.K.
        Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma.
        Cancer. 1975; 36: 123-128
        • Lokich J.J.
        • Ahlgren J.D.
        • Gullo J.J.
        • Philips J.A.
        • Fryer J.G.
        A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.
        J Clin Oncol. 1989; 7: 425-432
        • Leichman C.G.
        • Fleming T.R.
        • Muggia F.M.
        • Tangen C.M.
        • Ardalan B.
        • Doroshow J.H.
        • et al.
        Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study.
        J Clin Oncol. 1995; 13: 1303-1311
        • Chang A.E.
        • Schneider P.D.
        • Sugarbaker P.H.
        • Simpson C.
        • Culnane M.
        • Steinberg S.M.
        A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases.
        Ann Surg. 1987; 206: 685-693
        • Hohn D.C.
        • Stagg R.J.
        • Friedman M.A.
        • Hannigan Jr, J.F.
        • Rayner A.
        • Ignoffo R.J.
        • et al.
        A randomized trial of continuous intravenous versus hepatic intraarterial floxyuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.
        J Clin Oncol. 1989; 7: 1646-1654
        • Rougier P.
        • Laplanche A.
        • Huguier M.
        • Hay J.M.
        • Ollivier J.M.
        • Escat J.
        • et al.
        Hepatic arterial infusion of floxyuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial.
        J Clin Oncol. 1992; 10: 1112-1118
        • Meta-Analysis Group in Cancer
        Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
        J Natl Cancer Inst. 1996; 88: 252-258